All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: May 29, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

12

2023 to 2026

Breakthrough

1

Accelerated

0

Priority review

2

Orphan

0

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202340
202401
202560
202610

12 approvals

Newest first. Hover a badge for what it means.

  • Cypsedo (Cipepofol) · HaiscoMay 29, 2026
    Original approval · NDA 220482NovelApproval letter

    To induce general anesthesia in adults undergoing surgery

  • Bondlido (Lidocaine) · Medrx USASep 24, 2025
    Original approval · NDA 215029Approval letter
  • Vyscoxa (Celecoxib) · Carwin Pharm AssocJul 29, 2025
    Original approval · NDA 211759Approval letter
  • Xifyrm (Meloxicam) · AzurityJun 5, 2025
    Original approval · NDA 218395Approval letter
  • Qamzova (Meloxicam) · Nanjing DelovaApr 22, 2025
    Original approval · NDA 217593Approval letter
  • Symbravo (Meloxicam, Rizatriptan Benzoate) · AxsomeJan 30, 2025
    Original approval · NDA 215431Approval letter
  • Journavx (Suzetrigine) · Vertex Pharms INCJan 30, 2025
    Original approval · NDA 219209NovelBreakthrough therapyPriority reviewApproval letter

    To treat moderate to severe acute pain

  • Letybo (Letibotulinumtoxina-Wlbg) · Hugel INCFeb 29, 2024
    Original approval · BLA 761225NovelApproval letter

    To temporarily improve the appearance of moderate-to-severe glabellar lines

  • Coxanto (Oxaprozin) · SolubiomixOct 20, 2023
    Original approval · NDA 217927Approval letter
  • Combogesic Iv (Acetaminophen, Ibuprofen Sodium) · HikmaOct 17, 2023
    Original approval · NDA 215320Approval letter
  • Brixadi (Buprenorphine) · BraeburnMay 23, 2023
    Original approval · NDA 210136Priority reviewApproval letter
  • Combogesic (Acetaminophen, Ibuprofen) · Aft Pharms USMar 1, 2023
    Original approval · NDA 209471Approval letter

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.